{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rudolph KE"],"funding":["Columbia University","NIDA NIH HHS","National Institute on Drug Abuse"],"pagination":["109031"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8595679"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["228"],"pubmed_abstract":["<h4>Background</h4>Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high. It is possible that optimally matching patients with medication type would reduce risk of relapse. Our objective was to learn a rule by which to assign type of medication for OUD to reduce risk of relapse, and to estimate the extent to which risk of relapse would be reduced if such a rule were used.<h4>Methods</h4>This was a secondary analysis of an open-label randomized controlled, 24-week comparative effectiveness trial of injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days, or daily sublingual buprenorphine-naloxone (BUP-NX) for treating OUD, 2014-2017 (N = 570). Outcome was a binary indicator of relapse to regular opioid use during the 24 weeks of outp"],"journal":["Drug and alcohol dependence"],"pubmed_title":["Optimizing opioid use disorder treatment with naltrexone or buprenorphine."],"pmcid":["PMC8595679"],"funding_grant_id":["R00 DA042127"],"pubmed_authors":["Nunes EV","Diaz I","Luo SX","Rotrosen J","Rudolph KE"],"additional_accession":[]},"is_claimable":false,"name":"Optimizing opioid use disorder treatment with naltrexone or buprenorphine.","description":"<h4>Background</h4>Relapse rates during opioid use disorder (OUD) treatment remain unacceptably high. It is possible that optimally matching patients with medication type would reduce risk of relapse. Our objective was to learn a rule by which to assign type of medication for OUD to reduce risk of relapse, and to estimate the extent to which risk of relapse would be reduced if such a rule were used.<h4>Methods</h4>This was a secondary analysis of an open-label randomized controlled, 24-week comparative effectiveness trial of injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days, or daily sublingual buprenorphine-naloxone (BUP-NX) for treating OUD, 2014-2017 (N = 570). Outcome was a binary indicator of relapse to regular opioid use during the 24 weeks of outp","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-08T01:48:40.386Z","creation":"2025-04-19T22:47:24.235Z"},"accession":"S-EPMC8595679","cross_references":{"pubmed":["34534863"],"doi":["10.1016/j.drugalcdep.2021.109031"]}}